<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37457558</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Post-COVID sequelae effect in chronic fatigue syndrome: SARS-CoV-2 triggers latent adenovirus in the oral mucosa.</ArticleTitle><Pagination><StartPage>1208181</StartPage><MedlinePgn>1208181</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1208181</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1208181</ELocationID><Abstract><AbstractText>The post-viral fatigue syndromes long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have multiple, potentially overlapping, pathological processes. These include persisting reservoirs of virus, e.g., SARS-CoV-2 in long COVID patient's tissues, immune dysregulation with or without reactivation of underlying pathogens, such as Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV6), as we recently described in ME/CFS, and possibly yet unidentified viruses. In the present study we tested saliva samples from two cohorts for IgG against human adenovirus (HAdV): patients with ME/CFS (<i>n</i> =&#x2009;84) and healthy controls (<i>n</i> =&#x2009;94), with either mild/asymptomatic SARS-CoV-2 infection or no infection. A significantly elevated anti-HAdV IgG response after SARS-CoV-2 infection was detected exclusively in the patient cohort. Longitudinal/time analysis, before and after COVID-19, in the very same individuals confirmed HAdV IgG elevation after. In plasma there was no HAdV IgG elevation. We conclude that COVID-19 triggered reactivation of dormant HAdV in the oral mucosa of chronic fatigue patients indicating an exhausted dysfunctional antiviral immune response in ME/CFS, allowing reactivation of adenovirus upon stress encounter such as COVID-19. These novel findings should be considered in clinical practice for identification of patients that may benefit from therapy that targets HAdV as well.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Hannestad, Apostolou, Sj&#xf6;gren, Brag&#xe9;e, Polo, Bertilson and Ros&#xe9;n.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hannestad</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Surgery, Division of Cell Biology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostolou</LastName><ForeName>Eirini</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Surgery, Division of Cell Biology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;gren</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-Center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brag&#xe9;e</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-Center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polo</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>ME-Center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertilson</LastName><ForeName>Bo Christer</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-Center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ros&#xe9;n</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Surgery, Division of Cell Biology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">human adenovirus (HAdV)</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">oral mucosa immune response</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword><Keyword MajorTopicYN="N">saliva antibodies</Keyword></KeywordList><CoiStatement>PS, BBe, BBr, and OP declare disclosure of interest as having income from Brag&#xe9;e Clinics and BBr being a partial owner. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37457558</ArticleId><ArticleId IdType="pmc">PMC10349329</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1208181</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Gottfries C-G, Elfaitouri A, Rizwan M, Ros&#xe9;n A. Infection elicited autoimmunity and Myalgic encephalomyelitis/chronic fatigue syndrome: an explanatory model. Front Immunol. (2018) 9:229. doi: 10.3389/fimmu.2018.00229, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00229</ArticleId><ArticleId IdType="pmc">PMC5818468</ArticleId><ArticleId IdType="pubmed">29497420</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J Clin Pathol. (2007) 60:117&#x2013;9. doi: 10.1136/jcp.2006.042754, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2006.042754</ArticleId><ArticleId IdType="pmc">PMC1860613</ArticleId><ArticleId IdType="pubmed">16935963</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. . Myalgic encephalomyelitis: international consensus criteria. J Intern Med. (2011) 270:327&#x2013;38. doi: 10.1111/j.1365-2796.2011.02428.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. (2021) 27:895&#x2013;906. doi: 10.1016/j.molmed.2021.06.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cells. (2022) 185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, et al. . Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. (2018) 16:268. doi: 10.1186/s12967-018-1644-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald D, Ashley RL, Pearlman T, Kith P, Komaroff AL. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. J Med Virol. (1996) 50:25&#x2013;30. doi: 10.1002/(SICI)1096-9071(199609)50:1&lt;25::AID-JMV6&gt;3.0.CO;2-V, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199609)50:1&lt;25::AID-JMV6&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">8890037</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neal AJ, Glass KA, Emig CJ, Vitug AA, Henry SJ, Shungu DC, et al. . Survey of anti-pathogen antibody levels in Myalgic encephalomyelitis/chronic fatigue syndrome. Proteomes. (2022) 10:21. doi: 10.3390/proteomes10020021, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/proteomes10020021</ArticleId><ArticleId IdType="pmc">PMC9228258</ArticleId><ArticleId IdType="pubmed">35736801</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolou E, Rizwan M, Moustardas P, Sjogren P, Bertilson BC, Bragee B, et al. . Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Front Immunol. (2022) 13:949787. doi: 10.3389/fimmu.2022.949787, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.949787</ArticleId><ArticleId IdType="pmc">PMC9630598</ArticleId><ArticleId IdType="pubmed">36341457</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNeil KM, Dodge MJ, Evans AM, Tessier TM, Weinberg JB, Mymryk JS. Adenoviruses in medicine: innocuous pathogen, predator, or partner. Trends Mol Med. (2023) 29:4&#x2013;19. doi: 10.1016/j.molmed.2022.10.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.10.001</ArticleId><ArticleId IdType="pmc">PMC9742145</ArticleId><ArticleId IdType="pubmed">36336610</ArticleId></ArticleIdList></Reference><Reference><Citation>King CR, Zhang A, Mymryk JS. The persistent mystery of adenovirus persistence. Trends Microbiol. (2016) 24:323&#x2013;4. doi: 10.1016/j.tim.2016.02.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2016.02.007</ArticleId><ArticleId IdType="pubmed">26916790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med. (2016) 37:586&#x2013;602. doi: 10.1055/s-0036-1584923, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1584923</ArticleId><ArticleId IdType="pmc">PMC7171713</ArticleId><ArticleId IdType="pubmed">27486739</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. (2006) 93:491&#x2013;507. doi: 10.1093/biomet/93.3.491</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/93.3.491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieland L, Schwarz T, Engel K, Volkmer I, Kruger A, Tarabuko A, et al. . Epstein-Barr virus-induced genes and endogenous retroviruses in immortalized B cells from patients with multiple sclerosis. Cells. (2022) 11:3619. doi: 10.3390/cells11223619, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11223619</ArticleId><ArticleId IdType="pmc">PMC9688211</ArticleId><ArticleId IdType="pubmed">36429047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain V, Arunkumar A, Kingdon C, Lacerda E, Nacul L. Prevalence of and risk factors for severe cognitive and sleep symptoms in ME/CFS and MS. BMC Neurol. (2017) 17:117. doi: 10.1186/s12883-017-0896-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0896-0</ArticleId><ArticleId IdType="pmc">PMC5477754</ArticleId><ArticleId IdType="pubmed">28633629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. . Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. (2022) 603:321&#x2013;7. doi: 10.1038/s41586-022-04432-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. (2013) 11:205. doi: 10.1186/1741-7015-11-205, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-205</ArticleId><ArticleId IdType="pmc">PMC3847236</ArticleId><ArticleId IdType="pubmed">24229326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. Dermatol Ther. (2020) 33:e13878. doi: 10.1111/dth.13878, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13878</ArticleId><ArticleId IdType="pmc">PMC7323010</ArticleId><ArticleId IdType="pubmed">32558172</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Hou P, Ma W, Wang X, Wang H, Yu Z, et al. . SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy. Cell Mol Immunol. (2022) 19:67&#x2013;78. doi: 10.1038/s41423-021-00807-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00807-4</ArticleId><ArticleId IdType="pmc">PMC8628139</ArticleId><ArticleId IdType="pubmed">34845370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin A, Yan WH. Perspective of HLA-G induced immunosuppression in SARS-CoV-2 infection. Front Immunol. (2021) 12:788769. doi: 10.3389/fimmu.2021.788769, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.788769</ArticleId><ArticleId IdType="pmc">PMC8685204</ArticleId><ArticleId IdType="pubmed">34938296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. . Immune suppression in the early stage of COVID-19 disease. Nat Commun. (2020) 11:5859. doi: 10.1038/s41467-020-19706-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19706-9</ArticleId><ArticleId IdType="pmc">PMC7673112</ArticleId><ArticleId IdType="pubmed">33203833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science. (2015) 350:568&#x2013;71. doi: 10.1126/science.aab3291, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab3291</ArticleId><ArticleId IdType="pubmed">26405230</ArticleId></ArticleIdList></Reference><Reference><Citation>Stempel M, Chan B, Brinkmann MM. Coevolution pays off: herpesviruses have the license to escape the DNA sensing pathway. Med Microbiol Immunol. (2019) 208:495&#x2013;512. doi: 10.1007/s00430-019-00582-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-019-00582-0</ArticleId><ArticleId IdType="pubmed">30805724</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol. (2020) 15:389&#x2013;400. doi: 10.2217/fmb-2019-0288, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2019-0288</ArticleId><ArticleId IdType="pubmed">32166967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>